Passage BIO, Inc.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
PASG$3.78+10.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Six Months Ended | ||||||
| · · June 30, | ||||||
| (in thousands) · · 2026 · · 2025 | ||||||
| Cash flows used in operating activities: · · · · | ||||||
| Net loss | | $(15,380) | | $(24,790) | ||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | | | | | ||
| Depreciation and amortization | | 154 | | 370 | ||
| Share‑based compensation | | 1,081 | | 1,781 | ||
| Amortization of premium and discount on marketable securities, net | | | — | | | 129 |
| Net gain on lease terminations | | (2,577) | | — | ||
| Impairment of long-lived assets | | | — | | 2,637 | |
| Other non-cash items | | | — | | 14 | |
| Changes in operating assets and liabilities: | | | | | ||
| Prepaid expenses and other current assets, and other assets | | 105 | | (571) | ||
| Prepaid research and development | | 578 | | (66) | ||
| Non-refundable sublicense and transition services payments received | | | 2,500 | | | 1,515 |
| Right of use assets and operating lease liabilities | | | (7,332) | | | (215) |
| Accounts payable | | (211) | | 1,653 | ||
| Accrued expenses and other current liabilities | | (1,086) | | (2,634) | ||
| Net cash provided by (used in) operating activities | | (22,168) | | (20,177) | ||
| Cash flows provided by (used in) investing activities: | | | | | ||
| Sales or maturities of marketable securities | | — | | 39,046 | ||
| Sales of property and equipment and other assets | | 20 | | 1,170 | ||
| Net cash provided by (used in) investing activities | | 20 | | 40,216 | ||
| Cash flows provided by (used in) financing activities: | | | | | ||
| Proceeds from the issuance of common stock under employee stock purchase plan | | | — | | | 14 |
| Net cash provided by (used in) financing activities | | — | | 14 | ||
| Net increase (decrease) in cash and cash equivalents | | (22,148) | | 20,053 | ||
| Cash and cash equivalents at beginning of period | | 46,303 | | 37,573 | ||
| Cash and cash equivalents at end of period | | $24,155 | | $57,626 | ||
| Supplemental disclosure of non‑cash activities: | | | | | ||
| Unrealized gain (loss) on marketable securities | | $— | | $(8) | ||
See accompanying notes to unaudited interim consolidated financial statements.
Notes to Unaudited Interim Consolidated Financial Statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.